Septerna (SEPN) Stock Price & Analysis

SEPN$42.60+0.74 +1.77%
BiotechnologyGrowth StockHigh Quality
Compare
Market cap$2.03BEnterprise value$2.06BRevenue (TTM)$96.27MMarket position—

Score

64
Neutral
Value
55
Quality
64
Growth
73

AI Analysis

Snapshot

Septerna is a growth-led story right now — Growth 73/100 is the pillar doing the heavy lifting (overall 64/100) in Biotechnology. Under the hood: revenue compounding ~2393% annually over recent years. Street targets still imply ~18% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

55
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

73
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

64
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Septerna Inc (SEPN) last printed $42.60. Equity value is $2.03B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

202320242025
$151,000.00$1.07M$45.95M

About

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna (SEPN) Stock Price & Analysis

SEPN price $42.60 +0.74 +1.77%

Ticker
SEPN
Price
$42.60
Change
+0.74 +1.77%
Market cap
$2.03B
Dividend yield
0.00%
Beta
2.20
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
64
Value
55
Quality
64
Growth
73

Stocklytics score rationale: value 55, quality 64, growth 73.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener